From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences' antibody-oligonucleotide conjugate technology, to Nurix and Seagen collaborating on a targeted protein degradation conjugate, there is now a staggering amount of investment and collaboration in the novel conjugates space. As highlighted above, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma, Dyne Therapeuitcs and Alnylam are now […]

Cell therapy continues to transform the oncology field, and this year has also seen the translation of cell therapies’ curative potential into the autoimmune space. Providing your team with exclusive access to cutting-edge advances across pre-clinical platforms, clinical advances, and streamlined manufacturing, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of these innovations.   300+ […]

The Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Actively engage with the likes of Merck, Pfizer, SNIPR Biome, Locus Biosciences, Phiogen, AMR Action Fund and 90+ phage experts to demonstrate positive clinical data and patient outcomes. Take advantage of this unique opportunity to be a part of the dialogue, […]

With the cell and gene therapy industry surging, rapid advances in mRNA-based therapies, and the advent of DNA vaccines, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years. The DNA Process Development & Manufacturing Summit is the only industry-dedicated forum to focus on topics such as DNA construct design, sequencing technology, […]

We find ourselves at the cutting edge of oncology innovation, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations. As such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe. This meeting is the place […]

Returning for the seventh year, the 7th Antigen-Specific Immune Tolerance Summit (March 18 - 20, 2024 | Boston, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg, mRNA-LNP, biologic, peptide, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value […]

“The translational impact and nature of the work that was being presented were outstanding. You get a lot of insights from your peers regarding their experience interacting with the regulatory agencies” – ONK Tx The 9th Innate Killer Summit is designed for experts striving to realize the clinical potential of NK–based therapies from early discovery to later stages […]

Following the increasing interest in access to investigational medicines from patients, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise. Back in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading […]

The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this upcoming March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient […]

The Definitive Industry Forum for CKD Drug Development Advance More Personalized Therapies for Rare & Common Kidney Diseases The 6th CKD Drug Development Summit is the definitive forum for KOLs, industry experts, and regulators to bring kidney innovation onto the next generation of drug development, uniting 200+ biopharma stakeholders, from scientific research to clinical development […]

Step into the 2nd Targeted Intracellular Delivery Summit, a thrilling exploration of cutting-edge advancements in drug delivery. This year, we redefine possibilities, venturing beyond traditional boundaries with a focus on cellular biology and intracellular mechanisms. Optimize drug delivery, overcome endosomal challenges, and expand therapies beyond the liver with in-depth case studies and a Pre-Conference Workshop […]

In the dynamic cell therapy landscape, the challenge of potency assay development looms large, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years. At the 3rd Cell Therapy Potency Assay Summit, we bring together over 120 analytical, quality control, and regulatory experts including esteemed organizations like BMS, J&J, Atara Biotherapeutics, Fate Therapeutics, Health […]

Neuroimmunology targets in neurodegeneration are hotter than ever. Capturing biopharma’s latest research spanning discovery to early clinical development, the 6th Neuroimmunology Drug Development Summit is the industry-choice, comprehensive forum dedicated to translating neuroinflammatory-targeted therapeutics into clinical trials. What are the top features to look forward to in 2024? Doubled pre-conference workshop content, with 6 deep-dive […]

As the cell therapy field rapidly expands, keeping ahead of the race by creating a visible and robust supply chain has never been more critical to ensure you have the skills and strategy to develop into the next stage of your pipeline. Join us at the 5th Supply Chain & Logistics for Cell Therapies Summit […]

Accelerate patient value. Pioneer healthcare’s transformation.  Healthcare reforms are finally paving the way to affordable access to medicines, yet this progress threatens the development of future life-saving therapies. The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients. The key? Delivering aligned value to HCPs, patients, payers and […]

The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients. Discover innovative approaches to surpassing […]

This past year has seen more gene therapies approved by the FDA than the previous five years combined, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year. To maximize the value of your late-stage gene therapy […]